- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04950673
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients (COVID19)
Open-label, Post-marketing, Prospective, Two-Armed Comparison Study to Assess Impact of SARS-CoV-2 or COVID-19 on Cognitive Function in Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Cognivue is an FDA-cleared cognitive assessment device based on modern cognitive neuroscience, that allows physicians, allied healthcare providers, and patients to access a new approach to brain health, moving beyond the old questions and answers approach of traditional cognitive tests.
Cognivue's development and testing is based on 20 years of psychophysical and neurophysiological research that has focused on the early detection of patients' cognitive decline. Its FDA clearance study demonstrated significant correlation to the SLUMS and other neuropsychological tests, superior test re-test reliability compared to SLUMS, and validated its psychometric properties.
Historically, physicians have used the Mini-Mental Status Exam (MMSE) and Montreal Cognitive Assessment (MoCA) to assess cognitive functioning. These tools are often limited by issues of bias, inconsistent retest reliability, staffing and cost. The automated Cognivue technology utilizes adaptive psychophysics and assesses the patient's motor skills and visual acuity, eliminating the bias found in common cognitive testing mechanisms such as MMSE, MoCA, and Mini-Cog.
Using Cognivue Clarity, we have an opportunity to better understand a person in total when we insist that cognitive function testing is part of the recovery plan for individuals who experience the whiplash of COVID-19, either directly or indirectly.
This is a multi-site, open-label study. Approximately 1000 subjects will be enrolled. Up to 500 subjects with COVID-19 history and 500 subjects without a COVID-19 diagnosis will be enrolled in this study.
During the first visit, all subjects will be provided with an informed consent form (ICF) to review and sign prior to starting any study-specific procedures. Subjects will be asked about their COVID-19 diagnosis history, prior to study enrollment. After informed consent is obtained from subjects, study staff will review contact, demographic and medical history information. Following this review, cognitive testing using Cognivue Clarity, MMSE and MOCA will occur. In addition, subjects will take the Patient Health Questionnaire-9 (PHQ-9) and/or Geriatric Depression Scale (GDS) during this visit .
Subjects will be followed for 24 months in the study, coming to the study site to review COVID-19 infection (re-infection or newly diagnosed) as well as perform cognitive testing with Cognivue Clarity, MMSE and MOCA. Subjects will also take the PHQ-9 and/or GDS during these visits. In addition, during the 12- and 24-month visits, study staff will review previously reported medical history information with subjects to determine any new information.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92618
- RiiiD Research, LLC
-
Visalia, California, United States, 93291
- Kaweah Health (Kaweah Delta District Hospital)
-
-
Florida
-
Boca Raton, Florida, United States, 33431
- US Medical Care Inc
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- UH Cleveland Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years old
- Male or Female
- Previous diagnosis of COVID-19, but recovered >3 months (Arm 1)
- Never infected or diagnosed with COVID-19 (Arm 2)
- Fluent in English
- Able to operate simple computerized device
- Willing to sign a written informed consent and ability to comply with study requirements
- Ability to provide demographic and medical history information
Exclusion Criteria:
- Individuals under 18 years old
- Currently under COVID-19 treatment or quarantine
- Previously known diagnosis of dementia and Alzheimer's
- Inability to provide written informed consent for self or complete cognitive testing (either using Cognivue Clarity or paper/pencil testing)
- Known severe terminal illness
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subjects who had COVID-19 infection and recovered at 3 months
500 subjects who have had a history of COVID19 infection and recovered 3 months prior to the enrollment
|
Computerized Cognitive Assessment Device
|
Subjects who never had COVID-19 infection
500 subjects who never had a history of COVID19 infection prior to the enrollment
|
Computerized Cognitive Assessment Device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive decline
Time Frame: 24 months
|
The percentage of cognitive decline observed in both study arms (subjects with or without COVID-19 history) using assessments of Cognivue Clarity, Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison between Cognivue and other paper-pencil cognitive assessment batteries
Time Frame: 24 months
|
Depression and anxiety scales, i.e., Patient Health Questionnaire-9 (PHQ-9) or Geriatric Depression Scale (GDS).
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Diego Cahn-Hidalgo, MD, Cognivue, Inc.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- COVID19
- Cognition
- SARS-CoV2
- Cognivue
- Institutional Review Board or IRB
- Montreal Cognitive Assessment or MoCA
- Mini-Mental Status Exam or MMSE
- Patient Health Questionnaire or PHQ-9
- Food Drug Administration or FDA
- World Health Organization or WHO
- Informed Consent Form or ICF
- Case Report Form or CRF
- Good Clinical Practice or GCP
- Post CoV-2 Syndrome
- COVID Long-Haul
Additional Relevant MeSH Terms
- Mental Disorders
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurocognitive Disorders
- Cognition Disorders
- COVID-19
- Cognitive Dysfunction
Other Study ID Numbers
- COG-COVID19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Dysfunction
-
Mu Dong LiangNot yet recruitingPostoperative Cognitive Dysfunction(POCD)
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingPOCD - Postoperative Cognitive DysfunctionChina
-
Loma Linda UniversityCompleted1. Postoperative Cognitive DysfunctionUnited States
-
Xijing HospitalFirst Affiliated Hospital Xi'an Jiaotong University; Shanghai 10th People's... and other collaboratorsTerminatedPost Operative Cognitive DysfunctionChina
-
Icahn School of Medicine at Mount SinaiNational Institute on Aging (NIA)CompletedPost Operative Cognitive DysfunctionUnited States
-
Attikon HospitalCompleted
-
HealthPartners InstituteEnrolling by invitationPost Operative Cognitive DysfunctionUnited States
-
Burcu Ozalp HorsanaliCompletedPost Operative Cognitive Dysfunction
-
ImmunoChem Therapeutics, LLCNational Cancer Institute (NCI); Northwestern MedicineRecruitingCognitive Dysfunction, Cognitive DisorderUnited States
-
Mayo ClinicCompletedCognitive Impairment | Mild Cognitive Impairment | Neurocognitive DysfunctionUnited States